drugset / Trial / NCT00813995

A Study to Test the Safety and Efficacy of Adding Sitagliptin in Patients With Type 2 Diabetes Mellitus (MK0431-074)

NCT00813995

Phase 3 Completed 395 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to assess the safety and efficacy of the addition of sitagliptin compared to placebo in patients with Type 2 Diabetes Mellitus who have inadequate glycemic control on metformin.

Timeline

Start
2008-12-09
Primary completion
2010-08-09
Completion
2010-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 100 mg